These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results

Silence Therapeutics Plc SLN reported a loss for 2023 on Wednesday.

The company reported a loss per share of (38.9) pence for 2023, narrower than the (41.9) pence loss per share a year ago, according to data from Benzinga Pro. Collaboration revenues were £25.4 million versus £17.501 million a year ago. Net loss was £(43.3) million for 2023, compared to a net loss of £(40.5) million in 2022.

“We ended December 2023 with approximately $68.8 million and significantly increased our cash position in early 2024 to over $200 million,” said Rhonda Hellums, Chief Financial Officer of Silence.

Silence also announced topline 36-week data from the ongoing ALPACAR-360 phase 2 study of zerlasiran in patients with a median baseline Lp(a) of approximately 215 nmol/L.

“We are excited to have multiple programs advancing in the clinic, supported by a substantial cash position that extends our estimated runway into 2026,” Hellums added.

Silence Therapeutics shares fell 3.9% to close at $24.62 on Wednesday.

These analysts made changes to their price targets on Silence Therapeutics after announcing quarterly results.

  • Chardan Capital raised the price target on Silence Therapeutics from $26 to $42. Chardan Capital analyst Keay Nakae maintained a Buy rating.
  • Morgan Stanley boosted the price target on Silence Therapeutics from $29 to $45. Morgan Stanley analyst Michael Ulz maintained an overweight rating.

Check This Out: Tesla To $165? Here Are 10 Top Analyst Forecasts For Thursday

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPrice TargetSmall CapMarketsAnalyst RatingsTrading IdeasPT Changes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!